Rare Disease Report

Rare Disease Clinical Trials - Are They Measuring the Right Things?

FEBRUARY 27, 2017
Erika Augustine, MD

Erika Augustine, MD, of the University of Rochester talks about the need to have a dialog with the key players in the rare disease community (patients, clinicians, pharmaceutical companies, FDA) on what outcome measures are most appropriate in clinical trials involving rare diseases. 

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.